DOCSLIB.ORG

(TGM4) Gene and Its Potential Use for Prostate Cancer Gene Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(TGM4) Gene and Its Potential Use for Prostate Cancer Gene Therapy Regulation of the prostate-specific hTGP (TGM4) gene and its potential use for prostate cancer gene therapy. Guillermo Cipactl Rivera Gonzalez PhD University of York Biology Department DECEMBER 2011 Abstract Prostate cancer is a very important health problem in the UK and worldwide. Available treatments such as radiotherapy, surgery and androgen ablation have failed to significantly increase the life expectancy of prostate cancer patients. Therefore researching new treatments is paramount. A promising approach for prostate cancer is suicide gene therapy. In this work, the use of the NTR/CB1954 enzyme/prodrug system delivered by a baculovirus vector was investigated for its application in prostate cancer cell lines and prostate primary epithelial cultures. The results suggest that the NTR/CB1954 system is highly efficient in causing cell death in prostate cell lines and prostate primary epithelial cultures. The use of a baculovirus vector to deliver the NTR gene resulted in increased transduction of prostate cancer cell lines in comparison to non-malignant prostate and non-prostate cell lines. To target NTR expression to prostate cells the regulation of the hTGP promoter was dissected. hTGP expression was confirmed to be highly prostate specific and mainly regulated by retinoic acid, androgens, retinoic acid receptor gamma and the androgen receptor. This work presents the first evidence of an interaction between these nuclear receptors and challenges the current model for prostate specific expression. Finally a baculovirus encoding the NTR gene under the control of the hTGP promoter was tested in prostate cancer cell lines resulting in moderate cell death. These findings are very encouraging but in order to use the hTGP promoter for gene therapy there needs to be further manipulation of the sequence to optimise its potency while maintaining its prostate specificity The use of NTR and baculovirus coupled to the targeting controlled provided by the hTGP promoter could develop into a potent and specific approach to treat prostate cancer. 2 List of contents ABSTRACT ........................................................................................................ 2 LIST OF CONTENTS .......................................................................................... 3 LIST OF FIGURES AND TABLES ..................................................................... 8 ACKNOWLEDGEMENTS ................................................................................. 10 AUTHOR’S DECLARATION ............................................................................ 11 1. INTRODUCTION ........................................................................................... 12 1.1 PROSTATE ANATOMY AND PHYSIOLOGY ........................................................ 12 1.1.1 Prostate development ....................................................................... 15 1.1.2 Regulation of prostate development by hormones ........................... 15 1.2 STEROID RECEPTORS IN THE PROSTATE ....................................................... 17 1.2.1 Androgen receptor ............................................................................ 17 1.2.2 Retinoic acid receptors ..................................................................... 20 1.3 PROSTATE CANCER .................................................................................... 23 1.3.1 Risk factors for prostate cancer ........................................................ 23 1.3.2 Genes involved in prostate cancer ................................................... 25 1.4 AR AND CASTRATION-RESISTANT PROSTATE CANCER .................................... 29 1.5 PROSTATE CANCER STEM CELLS .................................................................. 32 1.6 CURRENT TREATMENTS FOR PROSTATE CANCER. ......................................... 35 1.6.1 Radical prostatectomy ...................................................................... 35 1.6.2 Radiotherapy ..................................................................................... 36 1.6.3 Androgen deprivation therapy ........................................................... 36 3 1.6.4 Chemotherapy .................................................................................. 37 1.7 Gene therapy as an alternative treatment for prostate cancer ............ 38 1.7.1 Viral vectors for gene therapy ........................................................... 39 1.8 GENE THERAPY STRATEGIES FOR PROSTATE CANCER ................................. 51 1.8.1 Corrective Gene therapy ................................................................... 51 1.8.3 Oncolytic Gene Therapy ................................................................... 52 1.8.4 Suicide Gene Therapy ...................................................................... 53 1.9 TARGETING VIRAL TROPISM ........................................................................ 57 1.9.1 Pseudotyping .................................................................................... 57 1.9.2 Adaptor Proteins ............................................................................... 57 1.9.3 Genetic Incorporation ........................................................................ 58 1.9.4 Transcriptional targeting ................................................................... 60 1.9.5 Human prostate-specific transglutaminase ....................................... 63 2. AIMS OF RESEARCH .................................................................................. 64 3. MATERIALS AND METHODS ..................................................................... 66 3.1 CELL CULTURE .......................................................................................... 66 3.1.1 Insect cell culture .............................................................................. 66 3.1.2 Human cell culture ............................................................................ 66 3.2 FOETAL CALF SERUM HORMONE DEPLETION ................................................. 67 3.3 SDS-PAGE AND WESTERN BLOT ............................................................... 68 3.4 RNA ISOLATION AND CDNA SYNTHESIS ....................................................... 69 3.5 GENERATION OF RECOMBINANT BACULOVIRUS ............................................. 70 3.6 VIRUS TITRATION ........................................................................................ 71 3.7 BACULOVIRUS AMPLIFICATION ..................................................................... 72 3.8 VIRAL DNA EXTRACTION ............................................................................ 72 4 3.9 VIRUS CONCENTRATION .............................................................................. 73 3.10 BACULOVIRUS TRANSDUCTION OF HUMAN CELLS ......................................... 73 3.11 RT-PCR AND RT-QPCR .......................................................................... 73 3.12 FLOW CYTOMETRY ................................................................................... 74 3.13 GENE EXPRESSION PROFILE IN HUMAN TISSUES .......................................... 75 3.14 BACTERIAL TRANSFORMATION ................................................................... 75 3.15 BACTERIAL CULTURES, PLASMID ISOLATION AND PURIFICATION .................... 75 3.16 GENERATION OF HTGP PROMOTER CONSTRUCTS ...................................... 76 3.17 IMMUNOFLUORESCENCE ........................................................................... 77 3.18 PLASMID TRANSFECTION INTO HUMAN CELL LINES ....................................... 78 3.19 PLASMID TRANSFECTION INTO SF9 INSECT CELLS ....................................... 79 3.20 LUCIFERASE ASSAY .................................................................................. 79 3.21 MTS ASSAY ............................................................................................. 79 3.22 SIRNA TRANSFECTION ............................................................................. 80 3.23 NTR HALF-LIFE ........................................................................................ 80 3.24 CHROMATIN IMMUNOPRECIPITATION (CHIP) ............................................... 81 4. RESULTS ..................................................................................................... 83 4.1 EFFICIENCY OF THE NTR/CB1954 SYSTEM IN PROSTATE CELLS .................... 83 4.1.1 Determining prostate cell lines’ sensitivity to CB1954 ...................... 83 4.1.2 NTR expression in prostate cancer cells triggers cell death after CB1954 treatment. ..................................................................................... 85 4.2 BACULOVIRUS AS A VECTOR FOR PROSTATE CANCER GENE THERAPY ............. 87 4.2.1 Baculovirus effectively transduces prostate cancer cell lines ........... 87 4.2.2 Baculovirus can efficiently transduce cultured cells derived from patients. ..................................................................................................... 91 5 4.3 HTGP PROMOTER CHARACTERIZATION ........................................................ 93 4.3.1 hTGP expression is highly prostate specific ..................................... 93 4.3.2 hTGP expression in prostate cell lines is controlled by retinoic acid 95 4.3.3 Prostate cell lines have different abilities to activate transcription following atRA treatment ............................................................................ 99 4.3.4 hTGP expression is repressed by androgens
Load more

Recommended publications
  • Genomic Variants Reveal Differential Evolutionary Constraints on Human Transglutaminases and Point Towards Unrecognized Significance of Transglutaminase 2
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Debrecen Electronic Archive RESEARCH ARTICLE Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2 Kiruphagaran Thangaraju1, RoÂbert KiraÂly1, MaÂte A. DemeÂny1, JaÂnos AndraÂs MoÂtyaÂn1, a1111111111 Mo nika Fuxreiter1,2, LaÂszlo FeÂsuÈs1,3* a1111111111 a1111111111 1 Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, a1111111111 Debrecen, Hungary, 2 MTA-DE Momentum Laboratory of Protein Dynamics, Faculty of Medicine, University a1111111111 of Debrecen, Debrecen, Hungary, 3 MTA-DE Stem cell, Apoptosis and Genomics Research Group of Hungarian Academy of Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary * [email protected] OPEN ACCESS Abstract Citation: Thangaraju K, KiraÂly R, DemeÂny MA, AndraÂs MoÂtyaÂn J, Fuxreiter M, FeÂsuÈs L (2017) Transglutaminases (TGMs) catalyze Ca2+-dependent transamidation of proteins with speci- Genomic variants reveal differential evolutionary constraints on human transglutaminases and point fied roles in blood clotting (F13a) and in cornification (TGM1, TGM3). The ubiquitous TGM2 towards unrecognized significance of has well described enzymatic and non-enzymatic functions but in-spite of numerous studies transglutaminase 2. PLoS ONE 12(3): e0172189. its physiological function in humans has not been defined. We compared data on non-syn- doi:10.1371/journal.pone.0172189 onymous single nucleotide variations (nsSNVs) and loss-of-function variants on TGM1-7 Editor: Richard L. Eckert, University of Maryland and F13a from the Exome aggregation consortium dataset, and used computational and School of Medicine, UNITED STATES biochemical analysis to reveal the roles of damaging nsSNVs of TGM2.
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • New Tools for Early Diagnosis of Breast and Genitourinary Cancers
    International Journal of Molecular Sciences Review Extracellular Vesicles: New Tools for Early Diagnosis of Breast and Genitourinary Cancers Anna Testa †, Emilio Venturelli † and Maria Felice Brizzi * Department of Medical Sciences, University of Turin, 10126 Turin, Italy; [email protected] (A.T.); [email protected] (E.V.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Breast cancers and cancers of the genitourinary tract are the most common malignancies among men and women and are still characterized by high mortality rates. In order to improve the outcomes, early diagnosis is crucial, ideally by applying non-invasive and specific biomarkers. A key role in this field is played by extracellular vesicles (EVs), lipid bilayer-delimited structures shed from the surface of almost all cell types, including cancer cells. Subcellular structures contained in EVs such as nucleic acids, proteins, and lipids can be isolated and exploited as biomarkers, since they directly stem from parental cells. Furthermore, it is becoming even more evident that different body fluids can also serve as sources of EVs for diagnostic purposes. In this review, EV isolation and characterization methods are described. Moreover, the potential contribution of EV cargo for diagnostic discovery purposes is described for each tumor. Keywords: oncology; extracellular vesicles; liquid biopsy Citation: Testa, A.; Venturelli, E.; Brizzi, M.F. Extracellular Vesicles: New Tools for Early Diagnosis of 1. Introduction Breast and Genitourinary Cancers. Cancer is a major public health problem representing the second cause of death world- Int. J. Mol. Sci. 22 2021, , 8430. wide after cardiovascular diseases.
    [Show full text]
  • Multivariate Gene Expression Analysis Reveals Functional Connectivity
    BMC Systems Biology BioMed Central Research article Open Access Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates André Fujita*1, Luciana Rodrigues Gomes2, João Ricardo Sato3, Rui Yamaguchi1, Carlos Eduardo Thomaz4, Mari Cleide Sogayar2 and Satoru Miyano1 Address: 1Human Genome Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan, 2Chemistry Institute, University of São Paulo, Av. Lineu Prestes, 748, São Paulo-SP, 05508-900, Brazil, 3Mathematics, Computation and Cognition Center, Universidade Federal do ABC, Rua Santa Adélia, 166 – Santo André, 09210-170, Brazil and 4Department of Electrical Engineering, Centro Universitário da FEI, Av. Humberto de Alencar Castelo Branco, 3972 – São Bernardo do Campo, 09850-901, Brazil Email: André Fujita* - [email protected] ; Luciana Rodrigues Gomes - [email protected]; João [email protected]; Rui Yamaguchi - [email protected]; Carlos Eduardo Thomaz - [email protected]; Mari Cleide Sogayar - [email protected]; Satoru Miyano - [email protected] * Corresponding author Published: 5 December 2008 Received: 29 August 2008 Accepted: 5 December 2008 BMC Systems Biology 2008, 2:106 doi:10.1186/1752-0509-2-106 This article is available from: http://www.biomedcentral.com/1752-0509/2/106 © 2008 Fujita et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Prostate cancer is a leading cause of death in the male population, therefore, a comprehensive study about the genes and the molecular networks involved in the tumoral prostate process becomes necessary.
    [Show full text]
  • Proteomic Profiling of Two Distinct Populations of Extracellular
    International Journal of Molecular Sciences Article Proteomic Profiling of Two Distinct Populations of Extracellular Vesicles Isolated from Human Seminal Plasma Xiaogang Zhang 1, Harmjan R. Vos 2 , Weiyang Tao 3 and Willem Stoorvogel 1,* 1 Department of Biomolecular Health Sciences, Faculty of Veterinary Science, Utrecht University, 3584 CM Utrecht, The Netherlands; [email protected] 2 Center for Molecular Medicine, Molecular Cancer Research Section, University Medical Center, 3584 CX Utrecht, The Netherlands; [email protected] 3 Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, Netherlands; [email protected] * Correspondence: [email protected] Received: 1 September 2020; Accepted: 22 October 2020; Published: 26 October 2020 Abstract: Body fluids contain many populations of extracellular vesicles (EV) that differ in size, cellular origin, molecular composition, and biological activities. EV in seminal plasma are in majority originating from prostate epithelial cells, and hence are also referred to as prostasomes. Nevertheless, EV are also contributed by other accessory sex glands, as well as by the testis and epididymis. In a previous study, we isolated EV from seminal plasma of vasectomized men, thereby excluding contributions from the testis and epididymis, and identified two distinct EV populations with diameters of 50 and 100 nm, respectively. In the current study, we comprehensively analyzed the protein composition of these two EV populations using quantitative Liquid Chromatography-Mass Spectrometry (LC-MS/MS). In total 1558 proteins were identified. Of these, 45% was found only in ≈ the isolated 100 nm EV, 1% only in the isolated 50 nm EV, and 54% in both 100 nm and 50 nm EV.
    [Show full text]
  • Supplementary Information – Postema Et Al., the Genetics of Situs Inversus Totalis Without Primary Ciliary Dyskinesia
    1 Supplementary information – Postema et al., The genetics of situs inversus totalis without primary ciliary dyskinesia Table of Contents: Supplementary Methods 2 Supplementary Results 5 Supplementary References 6 Supplementary Tables and Figures Table S1. Subject characteristics 9 Table S2. Inbreeding coefficients per subject 10 Figure S1. Multidimensional scaling to capture overall genomic diversity 11 among the 30 study samples Table S3. Significantly enriched gene-sets under a recessive mutation model 12 Table S4. Broader list of candidate genes, and the sources that led to their 13 inclusion Table S5. Potential recessive and X-linked mutations in the unsolved cases 15 Table S6. Potential mutations in the unsolved cases, dominant model 22 2 1.0 Supplementary Methods 1.1 Participants Fifteen people with radiologically documented SIT, including nine without PCD and six with Kartagener syndrome, and 15 healthy controls matched for age, sex, education and handedness, were recruited from Ghent University Hospital and Middelheim Hospital Antwerp. Details about the recruitment and selection procedure have been described elsewhere (1). Briefly, among the 15 people with radiologically documented SIT, those who had symptoms reminiscent of PCD, or who were formally diagnosed with PCD according to their medical record, were categorized as having Kartagener syndrome. Those who had no reported symptoms or formal diagnosis of PCD were assigned to the non-PCD SIT group. Handedness was assessed using the Edinburgh Handedness Inventory (EHI) (2). Tables 1 and S1 give overviews of the participants and their characteristics. Note that one non-PCD SIT subject reported being forced to switch from left- to right-handedness in childhood, in which case five out of nine of the non-PCD SIT cases are naturally left-handed (Table 1, Table S1).
    [Show full text]
  • W O 2019/200163 Al 17 October 2019 (17.10.2019) W IPO I PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property (1) Organization11111111111111111111111I1111111111111i1111liiili International Bureau (10) International Publication Number (43) International Publication Date W O 2019/200163 Al 17 October 2019 (17.10.2019) W IPO I PCT (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12N15/869 (2006.01) A61P17/00 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, C07K14/46 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2019/027079 pM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 11 April 2019 (11.04.2019) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regionalprotection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26)PublicationLanguage: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/656,768 12 April 2018 (12.04.2018) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: KRYSTAL BIOTECH, INC.
    [Show full text]
  • Loss of Heterozygosity for Defined Regions on Uterine Cervix
    British Joumal of Cancer (1998) 77(2), 192-200 © 1998 Cancer Research Campaign Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix AMF Kersemaekers1, J Hermans2, GJ Fleuren1 and MJ van de Vijver' Departments of 'Pathology and 2Statistics, Leiden University Hospital, PO Box 9600, Building 1, L1-Q, 2300 RC Leiden, The Netherlands Summary Loss of heterozygosity (LOH) frequently occurs in squamous cell carcinomas of the uterine cervix and indicates the probable sites of tumour-suppressor genes that play a role in the development of this tumour. To define the localization of these tumour-suppressor genes, we studied loss of heterozygosity in 64 invasive cervical carcinomas (stage IB and IIA) using the polymerase chain reaction with 24 primers for polymorphic repeats of known chromosomal localization. Chromosomes 3, 11, 13, 16 and 17, in particular, were studied. LOH was frequently found on chromosome 11, in particular at 11 q22 (46%) and 11 q23.3 (43%). LOH on chromosome 11p was not frequent. On chromosome 17p13.3, a marker (Dl 7S513) distal to p53 showed 38% LOH, whereas p53 itself showed only 20% LOH. On the short arm of chromosome 3, LOH was frequently found (41%) at 3p21.1. The f-catenin gene is located in this chromosomal region. Therefore, expression of f-catenin protein was studied in 39 cases using immunohistochemistry. Staining of 1-catenin at the plasma membrane of tumour cells was present in 38 cases and completely absent in only one case. The tumour-suppressor gene on chromosome 3p21.1 may be ,B-catenin in this one case, but (an)other tumour-suppressor gene(s) must also be present in this region.
    [Show full text]
  • Breakdown of Immune Tolerance in AIRE-Deficient Rats Induces A
    Breakdown of Immune Tolerance in AIRE-Deficient Rats Induces a Severe Autoimmune Polyendocrinopathy− Candidiasis−Ectodermal Dystrophy−like This information is current as Autoimmune Disease of September 23, 2021. Jason Ossart, Anne Moreau, Elodie Autrusseau, Séverine Ménoret, Jérôme C. Martin, Marine Besnard, Laure-Hélène Ouisse, Laurent Tesson, Léa Flippe, Kai Kisand, Pärt Peterson, François-Xavier Hubert, Ignacio Anegon, Régis Downloaded from Josien and Carole Guillonneau J Immunol published online 29 June 2018 http://www.jimmunol.org/content/early/2018/07/06/jimmun ol.1701318 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2018/06/28/jimmunol.170131 Material 8.DCSupplemental Why The JI? Submit online. by guest on September 23, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2018 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published July 6, 2018, doi:10.4049/jimmunol.1701318 The Journal of Immunology Breakdown of Immune Tolerance in AIRE-Deficient Rats Induces a Severe Autoimmune Polyendocrinopathy– Candidiasis–Ectodermal Dystrophy–like Autoimmune Disease Jason Ossart,*,† Anne Moreau,‡ Elodie Autrusseau,*,† Se´verine Me´noret,*,†,x Je´roˆme C.
    [Show full text]
  • Genome-Wide Association Study Suggests That Variation at the RCOR1 Locus Is Associated with Tinnitus in UK Biobank
    www.nature.com/scientificreports OPEN Genome‑wide association study suggests that variation at the RCOR1 locus is associated with tinnitus in UK Biobank Helena R. R. Wells1,2, Fatin N. Zainul Abidin2,3, Maxim B. Freidin1, Frances M. K. Williams1,4* & Sally J. Dawson2,4* Tinnitus is a prevalent condition in which perception of sound occurs without an external stimulus. It is often associated with pre‑existing hearing loss or noise‑induced damage to the auditory system. In some individuals it occurs frequently or even continuously and leads to considerable distress and difculty sleeping. There is little knowledge of the molecular mechanisms involved in tinnitus which has hindered the development of treatments. Evidence suggests that tinnitus has a heritable component although previous genetic studies have not established specifc risk factors. From a total of 172,608 UK Biobank participants who answered questions on tinnitus we performed a case–control genome‑wide association study for self‑reported tinnitus. Final sample size used in association analysis was N = 91,424. Three variants in close proximity to the RCOR1 gene reached genome wide signifcance: rs4906228 (p = 1.7E−08), rs4900545 (p = 1.8E−08) and 14:103042287_CT_C (p = 3.50E−08). RCOR1 encodes REST Corepressor 1, a component of a co‑repressor complex involved in repressing neuronal gene expression in non‑neuronal cells. Eleven other independent genetic loci reached a suggestive signifcance threshold of p < 1E−06. Tinnitus, ofen referred to as “ringing in the ears” has a reported prevalence of 10–15% in the adult population1–5 although the diagnosis and defnition of tinnitus remains inconsistent.
    [Show full text]
  • Transglutaminase 3: the Involvement in Epithelial Differentiation and Cancer
    cells Review Transglutaminase 3: The Involvement in Epithelial Differentiation and Cancer Elina S. Chermnykh * , Elena V. Alpeeva and Ekaterina A. Vorotelyak Koltzov Institute of Developmental Biology Russian Academy of Sciences, 119334 Moscow, Russia; [email protected] (E.V.A.); [email protected] (E.A.V.) * Correspondence: [email protected] Received: 1 June 2020; Accepted: 26 August 2020; Published: 30 August 2020 Abstract: Transglutaminases (TGMs) contribute to the formation of rigid, insoluble macromolecular complexes, which are essential for the epidermis and hair follicles to perform protective and barrier functions against the environment. During differentiation, epidermal keratinocytes undergo structural alterations being transformed into cornified cells, which constitute a highly tough outermost layer of the epidermis, the stratum corneum. Similar processes occur during the hardening of the hair follicle and the hair shaft, which is provided by the enzymatic cross-linking of the structural proteins and keratin intermediate filaments. TGM3, also known as epidermal TGM, is one of the pivotal enzymes responsible for the formation of protein polymers in the epidermis and the hair follicle. Numerous studies have shown that TGM3 is extensively involved in epidermal and hair follicle physiology and pathology. However, the roles of TGM3, its substrates, and its importance for the integument system are not fully understood. Here, we summarize the main advances that have recently been achieved in TGM3 analyses in skin and hair follicle biology and also in understanding the functional role of TGM3 in human tumor pathology as well as the reliability of its prognostic clinical usage as a cancer diagnosis biomarker. This review also focuses on human and murine hair follicle abnormalities connected with TGM3 mutations.
    [Show full text]
  • The University of Chicago Identification And
    THE UNIVERSITY OF CHICAGO IDENTIFICATION AND CHARACTERIZATION OF REGULATORY T CELLS THAT RECOGNIZE NATURAL EPITOPES A DISSERTATION SUBMITTED TO THE FACULTY OF THE DIVISION OF THE BIOLOGICAL SCIENCES AND THE PRITZKER SCHOOL OF MEDICINE IN CANDIDACY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY COMMITTEE ON IMMUNOLOGY BY DANA CATHERINE GILMORE CHICAGO, ILLINOIS MARCH 2018 Table of Contents List of Figures ………………………………………………………………………………….. vi List of Tables ………………………………………………………………………………….. vii List of Abbreviations………………………………………………………………………….. viii Acknowledgments ……………………………………………………………………………... x Abstract ………………………………………………………………………………………... xii Chapters I. Introduction ………………………………………………………………………………1 T Cell Tolerance ……………….............……………………………………….3 Identification of Regulatory T Cells ...………………………………………….4 Mechanisms of Treg Suppression ..…………………………………………...7 Generation of T Cell Receptor Diversity ..……………………………………10 T Cell Selection ..………………………………………………………………12 Models of T Cell Selection ..…………………………………….…………….16 Thymic Treg Development ……………………………………………………19 Promiscuous Gene Expression in the Thymus ……………………………..24 Nature of Antigens Recognized by tTreg Cells ……………………………..27 Peripheral Treg Development ..…………………...………………………….28 Homeostasis and Maintenance of Treg Cells in the Periphery ..…………..30 ii Treg Stability ..………………………………………………………………….31 Conclusion .………………………………………………………………….....32 II. Materials and Methods ..…………………………………………………...…………34 Mice …………….………………………………………………………………34 Preparation of prostatic extracts .………………………………………….…34
    [Show full text]